Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P51654

UPID:
GPC3_HUMAN

ALTERNATIVE NAMES:
GTR2-2; Intestinal protein OCI-5; MXR7

ALTERNATIVE UPACC:
P51654; C9JLE3; G3V1R0; Q2L880; Q2L882

BACKGROUND:
The protein Glypican-3, with aliases GTR2-2, Intestinal protein OCI-5, and MXR7, serves as a crucial regulator in multiple biological processes. It negatively regulates the hedgehog signaling pathway, aids in the positive regulation of both canonical and non-canonical Wnt signaling pathways, and plays a significant role in limb patterning, skeletal development, and coronary vascular development.

THERAPEUTIC SIGNIFICANCE:
Involvement of Glypican-3 in Simpson-Golabi-Behmel syndrome 1, marked by gigantism, facial dysmorphism, and cardiac defects, underscores its therapeutic significance. Exploring Glypican-3's functions and mechanisms could lead to innovative treatments for this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.